Sleep Disorders: Pathophysiology, Clinical Evaluation, and Evidence-Based Management of Insomnia

Sleep disorders are a group of conditions characterized by impaired sleep quantity, quality, timing, or behavior during sleep, leading to clinically significant distress or daytime impairment. The most common and widely recognized sleep disorder is insomnia, defined by difficulty initiating sleep, difficulty maintaining sleep, early-morning awakening, or nonrestorative sleep, occurring despite adequate opportunity and resulting in fatigue, impaired concentration, mood disturbance, and reduced quality of life.

Mechanistically, insomnia is frequently conceptualized through hyperarousal models. Hyperarousal involves heightened cognitive, physiologic, and neurobiologic activation that persists at night. At the physiologic level, increased sympathetic activity and elevated stress mediators can disrupt sleep onset and continuity. At the cognitive level, dysfunctional beliefs about sleep, conditioned arousal (the bed becomes a cue for wakefulness), and attentional bias toward sleep-related threats perpetuate wakefulness. Neurobiologically, dysregulation of arousal systems (including orexin/hypocretin, histaminergic signaling, and GABAergic inhibition pathways) can destabilize the balance between wakefulness and sleep.

Insomnia often coexists with psychiatric and medical conditions, including major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, chronic pain syndromes, and cardiopulmonary illnesses. Circadian rhythm disturbances, such as delayed or advanced sleep-wake phase disorder, can present as insomnia-like symptoms because sleep occurs at an inappropriate biological time. Substance and medication effects are also central: caffeine, nicotine, alcohol (which may fragment sleep later), stimulants, corticosteroids, some antidepressants, and beta-agonists can all alter sleep architecture and increase awakenings.

Clinically, evaluation begins with a focused sleep history. Key elements include sleep timing, total sleep time, sleep latency, number and duration of awakenings, early morning awakenings, and subjective sleep quality. Patients should be screened for snoring, witnessed apneas, choking/gasping during sleep, restless legs sensations, circadian misalignment, and sleep-related behaviors. The presence of comorbid mood symptoms, panic symptoms, substance use, and chronic pain should be assessed. A sleep diary and actigraphy can help distinguish behavioral insomnia from circadian disorders and quantify patterns over time.

Validated questionnaires support standardized assessment. The Insomnia Severity Index (ISI) measures symptom severity and treatment response. If restless legs syndrome is suspected, clinicians use diagnostic criteria emphasizing an urge to move the legs with uncomfortable sensations that worsen during rest and improve with movement. If obstructive sleep apnea is suspected—particularly in patients with obesity, daytime sleepiness, hypertension, or loud snoring—polysomnography or home sleep apnea testing is often indicated.

Management is best guided by etiology and risk stratification. First-line therapy for chronic insomnia is cognitive behavioral therapy for insomnia (CBT-I). CBT-I combines stimulus control (associating bed with sleep and sex rather than wakefulness), sleep restriction therapy (temporarily limiting time in bed to consolidate sleep while maintaining safety), cognitive restructuring (challenging maladaptive sleep beliefs), and relaxation strategies. These interventions reduce conditioned arousal and normalize sleep drive by improving sleep homeostasis and decreasing cognitive/physiologic hyperarousal.

Sleep hygiene alone is insufficient for most chronic insomnia, but it can augment CBT-I. Recommended practices include consistent wake times, limiting late caffeine, avoiding nicotine close to bedtime, minimizing alcohol’s late effects, reducing screen exposure before sleep, and using the bed only for sleep and sex. For short-term relief, clinicians may consider pharmacotherapy, typically as an adjunct to CBT-I rather than a standalone long-term solution. Options may include melatonin receptor agonists or sedative-hypnotics in selected cases, with careful attention to adverse effects such as next-day impairment, falls risk, tolerance, dependence potential, and complex sleep behaviors.

When insomnia is secondary to comorbid conditions, treating the underlying driver is essential. Depression and anxiety require appropriate psychotherapy and/or pharmacotherapy. Chronic pain management often combines behavioral interventions, pharmacologic approaches tailored to pain type, and when relevant, interdisciplinary care. For circadian rhythm disorders, light therapy and timed chronotherapy can shift the sleep-wake phase.

Because insomnia is associated with downstream outcomes—including impaired cognition, increased accident risk, cardiovascular morbidity, and worse mental health—early identification and targeted therapy are clinically important. Prognosis is favorable when patients receive structured behavioral treatment and the underlying perpetuating factors are addressed.

Source: [@dastardlyhalves / Jun 19, 2026].